Publications
(currently under modification
)

Public disseminations: 
 

Meeting contributions:

2009:

ESGCT meeting, Hannover, Germany: Tissue-specific targeting of lentiviral vectors using neuronal or glial promoters and various pseudotyping. Delzor et al.

2010:

Francophone Society of Cell and Gene Therapy (SFTCG) meeting, Paris, France. Pre-clinical studies of neurodegenerative diseases. Déglon et al.

FENS-IBRO Summer School on translational research in basal ganglia disorders, Mallorca, Spain. Genetic models of neurodegenerative diseases. Déglon et al.

Society for Neuroscience Meeting, San Diego, USA.  Tissue-specific targeting of lentiviral vectors using neuronal or astrocytic promoters and various pseudotyping. Delzor, et al.

16th Annual meeting of the German Society of Neurogenetics : « Functional Genomics of Parkinson’s disease », Tuebingen, Germany. Viral gene delivery to nigral neurons: animal models of Parkinson’s disease in prelude to neuroprotective therapies. Schneider B.L.

Swiss Society for Neuroscience, Zürich, Switzerland. The potential of viral tools: from optogenetics to gene therapy - Symposium « Viral Strategies in Brain Research », Schneider B.L.

12th International Neuroscience Winter Conference, Soelden, Austria Adeno-associated vectors to model and treat Parkinson’s disease. Schneider B.L.

World Parkinson Congress, Glasgow, UK Alpha-synuclein animal models. Schneider B.L.

World Parkinson Congress, Glasgow, UK  Effective delivery of the neuroprotectant to the brain. Schneider B.L.

40th Annual Meeting of the Neuroscience Society 2010, San Diego, USA The therapeutic potential of PGC-1α in Parkinson’s disease: promise and pitfalls.
Ciron C., Bensadoun J.C., Canto-Alvarez C., Mlynarik V., Schneider B.L., Aebischer P.

40th Annual Meeting of the Neuroscience Society 2010, San Diego, USA
 Adeno-associated mifepristone-regulated viral vector system for controllable GDNF expression in the central nervous system. Tereshchenko Y., Maddalena A., Bähr M., Kügler S.

 

2011:

41th Annual Meeting of the Neuroscience Society 2011, Washington DC, USA
Knock-down of PGC-1α expression increases vulnerability to human α-synuclein in nigral dopaminergic neurons. Ciron C., Kelly D.P., Padrun V., Aebischer P., Schneider B.L.

41th Annual Meeting of the Neuroscience Society 2011, Washington DC, USA Adeno-associated mifepristone-regulated viral vector system for controllable GDNF expression in astrocytes provides therapeutic effects in the 6-OHDA Parkinson disease model. Tereshchenko Y, Bähr M., Kügler S.

CMPB symposium “A bridge between microscopy and neuroscience”, Goettingen, Germany Gene delivery to the adult central nervous system to explore genetic determinants of aging and neurodegeneration. Schneider B.L.

 

Published papers:

Engineered lentiviral vector targeting astrocytes in vivo.
Colin A, Faideau M, Dufour N, Auregan G, Hassig R, Andrieu T, Brouillet E, Hantraye P, Bonvento G, Déglon N.
Glia. 2009 Apr 15;57(6):667-79.

Optimization of continuous in vivo DOPA production and studies on ectopic DA synthesis using rAAV5 vectors in Parkinsonian rats.
Björklund T, Hall H, Breysse N, Soneson C, Carlsson T, Mandel RJ, Carta M, Kirik D.
J Neurochem. 2009 Oct;111(2):355-67

Dose optimization for long-term rAAV-mediated RNA interference in the nigrostriatal projection neurons.
Ulusoy A, Sahin G, Björklund T, Aebischer P, Kirik D.
Mol Ther. 2009 Sep;17(9):1574-84

In vivo expression of polyglutamine-expanded huntingtin by mouse striatal astrocytes impairs glutamate transport: a correlation with Huntington's disease subjects.
Faideau M, Kim J, Cormier K, Gilmore R, Welch M, Auregan G, Dufour N, Guillermier M, Brouillet E, Hantraye P, Déglon N, Ferrante RJ, Bonvento G.
Hum Mol Genet. 2010 Aug 1;19(15):3053-67.

Optimized adeno-associated viral vector-mediated striatal DOPA delivery restores sensorimotor function and prevents dyskinesias in a model of advanced Parkinson's disease.
Björklund T, Carlsson T, Cederfjäll EA, Carta M, Kirik D.
Brain. 2010 Feb;133(Pt 2):496-511.

Glutathione depletion and overproduction both initiate degeneration of nigral dopaminergic neurons.
Garrido M, Tereshchenko Y, Zhevtsova Z, Taschenberger G, Bähr M, Kügler S.
Acta Neuropathol. 2011 Apr;121(4):475-85.

Efficient gene therapy for Parkinson's disease using astrocytes as hosts for localized neurotrophic factor delivery.
Drinkut A, Tereshchenko Y, Schulz JB, Bähr M, Kügler S.
Mol Ther. 2012 Mar;20(3):534-43.

Aggregation of αSynuclein promotes progressive in vivo neurotoxicity in adult rat dopaminergic neurons.
Taschenberger G, Garrido M, Tereshchenko Y, Bähr M, Zweckstetter M, Kügler S.
Acta Neuropathol. 2011 Dec 14. [Epub ahead of print]

Key factors determining the efficacy of gene therapy for continuous DOPA delivery in the Parkinsonian brain.
Cederfjäll E, Sahin G, Kirik D.
Neurobiol Dis. 2011 Oct 25. [Epub ahead of print]

Nigrostriatal overabundance of α-synuclein leads to decreased vesicle density and deficits in dopamine release that correlate with reduced motor activity.
Gaugler MN, Genc O, Bobela W, Mohanna S, Ardah MT, El-Agnaf OM, Cantoni M, Bensadoun JC, Schneggenburger R, Knott GW, Aebischer P, Schneider BL.
Acta Neuropathol. 2012 Feb 24. [Epub ahead of print]

Sustained expression of PGC-1α in the rat nigrostriatal system selectively impairs dopaminergic function.
Ciron C, Lengacher S, Dusonchet J, Aebischer P, Schneider BL.
Hum Mol Genet. 2012 Jan 19. [Epub ahead of print]

Design of a Single AAV Vector for Coexpression of TH and GCH1 to Establish Continuous DOPA Synthesis in a Rat Model of Parkinson's Disease.
Cederfjäll E, Sahin G, Kirik D, Björklund T.
Mol Ther. 2012 Jan 31. doi: 10.1038/mt.2012.1. [Epub ahead of print]